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A B S T R A C T
Purpose
Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival
for patients with colorectal cancer, although its effectiveness in the Medicare population
is uncertain.
Patients and Methods
Using the Surveillance, Epidemiology, and End Results (SEER) -Medicare linked database, we
identified 2,526 patients with stage IV colorectal cancer diagnosed between 2002 and 2007 who
received first-line combination chemotherapy with a fluoropyrimidine and either irinotecan (33%)
or oxaliplatin (67%). Thirty-six percent of patients received bevacizumab with first-line therapy. The
primary outcome was overall survival. Secondary outcomes were bevacizumab-associated toxic-
ities, including the incidence of stroke, myocardial infarction, and GI perforation.
Results
In the primary cohort inclusive of patients diagnosed between 2002 and 2007, bevacizumab
with combination chemotherapy was associated with improved overall survival (adjusted hazard
ratio [HR], 0.85; 95% CI, 0.78 to 0.93), although the effect was more modest when restricted to
years 2004 to 2007 (HR, 0.93; 95% CI, 0.84 to 1.02). The observed survival advantage of
bevacizumab was more apparent with irinotecan-based chemotherapy (HR, 0.80; 95% CI, 0.66 to
0.97) than with oxaliplatin-based chemotherapy (HR, 0.96; 95% CI, 0.86 to 1.07). Combination
chemotherapy with bevacizumab, versus combination chemotherapy without bevacizumab, was
associated with increased risk of stroke (4.9% v 2.5%, respectively; P  .01) and GI perforation
(2.3% v 1.0%, respectively; P  .01). Cardiac events and venous thrombosis were not increased
with bevacizumab.
Conclusion
The addition of bevacizumab to cytotoxic combination chemotherapy was associated with small
improvement in overall survival as well as increased risk of stroke and perforation, but not cardiac
events, among Medicare beneficiaries with stage IV colorectal cancer.
J Clin Oncol 30:608-615. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Before 1998, intravenous fluoropyrimidine therapy
was the only efficacious option for metastatic colo-
rectal cancer, extending median survival from 6
months without therapy to 1 year.1 Over the last 13
years, additional drugs have entered the landscape,
including two other cytotoxic drugs (irinotecan and
oxaliplatin) and targeted monoclonal antibodies
(bevacizumab, cetuximab, and panitumumab).
First-line randomized controlled trials demon-
strated that adding either irinotecan or oxaliplatin to
fluoropyrimidines improves median survival by 2 to
4 months.2-4 In the United States, a weekly bolus
regimen of irinotecan, fluorouracil (FU), and leuco-
vorin (IFL) was initially embraced as the stan-
dard regimen for chemotherapy-naive patients.
Subsequent trials demonstrated that infusional fluo-
ropyrimidine regimens with either oxaliplatin (infu-
sional FU, leucovorin, and oxaliplatin [FOLFOX])
or irinotecan (FU, leucovorin, and irinotecan
[FOLFIRI]) are more efficacious5,6 and less toxic5
than IFL, leading to a shift from IFL to FOLFOX or
FOLFIRI in the mid-2000s.
Bevacizumab, an antibody against the vascular
endothelial growth factor, was initially approved by
the US Food and Drug Administration (FDA) in
2004 with FU-based chemotherapy as first-line
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treatment of metastatic colorectal cancer.7 The pivotal trial demon-
strated that bevacizumab added to IFL improved median survival
from 15.6 to 20.3 months (P  .001).8 In a subsequent trial, bevaci-
zumab added to fluoropyrimidine and oxaliplatin improved median
overall survival more modestly (21.3 months with bevacizumab v 19.9
months without bevacizumab; P  .08).9
The trials that led the FDA to approve bevacizumab in first-line
metastatic colorectal cancer treatment addressed the question of clin-
ical efficacy in patients who met stringent eligibility criteria and were
typically younger and healthier than the typical patient with metastatic
colorectal cancer. Effectiveness studies examine the impact of treat-
ment in the context of usual care settings, often in populations more
diverse by age, race, and health status. To understand the balance of
benefits and harms in such a nonclinical trial setting, we used the
Surveillance, Epidemiology, and End Results (SEER) -Medicare
linked database to compare the effectiveness of cytotoxic chemother-
apy treatment with and without bevacizumab in newly diagnosed
stage IV colorectal cancer.
PATIENTS AND METHODS
Data Sources
The study cohort was derived from the SEER-Medicare database, which
links patient demographic and tumor-specific data collected by SEER cancer
registries to the Medicare claims files from the Centers for Medicare and
Medicaid Services.10 Information on patients with new incident cancers was
available from 16 cancer registries from 2002 to 2007, covering approximately
26% of the US population. Data on cancer site, extent of disease, histologic
findings, date of diagnosis, and initial treatment are available. Date of death
was identified from Medicare enrollment records, with follow-up through
December 31, 2009, allowing for at least 2 years of follow-up for each patient.
Medicare provides health care benefits to 97% of the US population age 65
years or older. Claim histories permit ascertainment of the specific chemother-
apy administered. Approximately 94% of SEER patients age 65 years or older
have been linked with their Medicare claims.11
Cohort Definition
The cohort included all patients age 65 and older who were diagnosed
between 2002 and 2007 with colorectal cancer in a SEER area (see Appendix
Table A1, online only, for codes used). To assume complete ascertainment of
health services, the study sample included all individuals with complete claims,
including those with continuous enrollment in Medicare Part A and B and
non–health maintenance organization enrollment during the study period.
To be included in the cohort (Fig 1), patients needed to be diagnosed
with stage IV colon or rectal cancer and treated with a fluoropyrimidine (either
FU or capecitabine) and either oxaliplatin or irinotecan within 6 months of
diagnosis. Patients originally diagnosed with early-stage disease who experi-
enced recurrence were not included. The first dose of oxaliplatin or irinotecan
must have been billed within 1 month of the first dose of fluoropyrimidine to
avoid capturing second-line instead of first-line treatment. Patients classified
as receiving bevacizumab received their first dose of bevacizumab within 1
month of the first dose of chemotherapy.
Because alternative cytotoxic regimens may have different efficacy and
effectiveness profiles, we scrutinized claims histories to distinguish whether the
chemotherapy backbone was IFL (2 to 4 weeks treatment once per week
followed by 1- to 2-week break), FOLFIRI (infusional regimen every other
week), FOLFOX, or capecitabine plus oxaliplatin. Patients classified as receiv-
ing IFL received irinotecan before 2004, or the intervals between irinotecan
infusions were 8 days or less on two occasions. Patients classified as receiving
FOLFIRI had intervals between irinotecan of 14 days or greater or had charges
for an infusion pump (Appendix Table A1).
Bevacizumab was approved by the FDA in February 2004. In our pri-
mary analyses (cohort 1), we assume that the care of patients with metastatic
colorectal cancer was not sufficiently different outside of the use of bevaci-
zumab from 2002 to 2007. Inclusion of years before FDA approval of bevaci-
zumab addresses concerns for bias by indication because lack of use of
bevacizumab after 2004 may be indicative of reasons that may impact survival
(although we do adjust by comorbidity in adjusted analyses). However, in
sensitivity analyses, we restricted the cohort to patients diagnosed between
2004 and 2007 (cohort 2), when bevacizumab was commercially available and
other medications for later-line therapy were available for usage (eg, cetux-
imab and panitumumab). Furthermore, for patients receiving irinotecan and
fluoropyrimidine, there was an increasing shift from IFL to FOLFIRI after
2004, and thus, the cytotoxic chemotherapy regimens FOLFOX and FOLFIRI
are more comparable in cohort 2.
End Point Definitions
The primary end point was overall survival, which was defined as the
interval between date of first dose of chemotherapy and date of death as
Diagnosed between 2002 and 2007




Diagnosis at stage IV
(n = 16,039)
With part A and B for 6 months 
after diagnosis 
(n = 14,972)
Without HMO for 6 months 
after diagnosis
(n = 11,311)
Any chemotherapy within 6 months 
after diagnosis
(n = 5,139)
Patients treated with FU 
or capecitabine 
(n = 4,365)
Patients treated with oxaliplatin or
irinotecan with first dose within 30
days of fluoropyrimidine 
(n = 2,526)
Fig 1. Cohort definition. (*) Small percentage of patients will ultimately be
diagnosed after death. FU, fluorouracil; HMO, health maintenance organization.
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reported to Medicare or December 31, 2009, whichever occurred first. Second-
ary end points were inpatient and outpatient events associated with bevaci-
zumab, including cardiac toxicity, stroke, venous thrombosis, and GI
perforation (Appendix Table A1).8
Patient Characteristics Associated With
Treatment and Outcomes
Using the SEER-Medicare files, we evaluated clinical characteristics, de-
mographic data, and the Deyo-Charlson-Klabunde comorbidity index.12 The
comorbidity index includes myocardial infarction, congestive heart failure,
peripheral vascular disease, and cardiovascular and cerebrovascular disease,
thereby capturing many of the absolute or relative contraindications to bev-
acizumab. All available inpatient and outpatient Medicare claims were exam-
ined for the period between 13 months and 1 month before the diagnosis of
stage IV colorectal cancer, and patients were scored by maximal comorbidity
observed (0, 1, or 2).
Statistical Considerations
Overall survival was examined using the Kaplan-Meier method13 and
Cox proportional hazards regression for both the 2002 to 2007 and 2004 to
2007 cohorts.14 Multivariable modeling was used to adjust for potential con-
founders and propensity scores15 to further examine for potential treatment
selection bias.
Toxicity analyses were performed using logistic regression modeling,
adjusting for potential confounders as well as propensity scores.15 All analyses
used SAS version 9.1 (SAS Institute, Cary, NC). All P values are two-sided.
Table 1. Baseline Demographics and Clinical Characteristics for Medicare
Beneficiaries With Stage IV Colorectal Cancer Diagnosed in a



















65-69 619 38.1 334 37.0
70-74 461 28.4 271 29.9
75-79 373 23.0 200 22.1
80 170 10.5 98 10.8
Sex
Female 769 47.4 418 46.3
Male 854 52.6 485 53.7
Race
White 1,416 87.2 790 87.5
Black 131 8.1 69 7.6
Other 76 4.7 44 4.9
Comorbidity
0 1,098 67.7 606 67.1
1 361 22.2 190 21.1
2 164 10.1 107 11.8
Marital status
Married 1,017 62.7 559 61.9
Single 124 7.6 71 7.9
Widowed/divorced 430 26.5 232 25.7
Other 52 3.2 41 4.5
Site of primary
Colon 1,246 76.8 716 79.3
Rectal 377 23.2 187 20.7
Surgery for primary tumor†
Yes 1,217 75.0 688 76.2
No 406 25.0 215 23.8
Tumor grade
Well or moderately differentiated 957 59.0 521 57.7
Poorly differentiated 447 27.5 257 28.5
Unknown 219 13.5 125 13.8
Median income‡
Top quantile 401 24.7 231 25.6
Second quantile 402 24.8 229 25.4
Third quantile 402 24.8 229 25.4
Bottom quantile 417 25.7 214 23.7
Geographic category for registry
Northeast 393 24.2 193 21.4
South 302 18.6 193 21.4
Midwest 247 15.2 148 16.4
West 681 42.0 369 40.9
Year of diagnosis
2002 291 18.0 — —
2003 316 19.5 — —
2004 444 27.4 58 6.4
2005 193 11.9 300 33.2
2006 181 11.2 284 31.5
2007 198 12.2 261 28.9
(continued in next column)
Table 1. Baseline Demographics and Clinical Characteristics for Medicare
Beneficiaries With Stage IV Colorectal Cancer Diagnosed in a SEER Registry



















Oxaliplatin based 936 57.7 744 82.3
IV FU and oxaliplatin 794 682
Capecitabine and oxaliplatin 142 62
Irinotecan based 687 42.3 159 17.7
Bolus (IFL) 548 31
Infusional (FOLFIRI)§ 139 128
Latter-line therapies received
Irinotecan first line
Oxaliplatin 303 44.1 77 48.4
EGFR inhibitor 228 33.2 54 34.0
Oxaliplatin first line
Irinotecan 469 50.1 414 55.6
EGFR inhibitor 380 40.5 276 37.1
Abbreviations: EGFR, epidermal growth factor receptor; FOLFIRI, fluorou-
racil, leucovorin, and irinotecan; FU, fluorouracil; IFL, irinotecan, fluoroura-
cil, and leucovorin; IV, intravenous; SEER, Surveillance, Epidemiology, and
End Results.
The Deyo-Charlson-Klabunde comorbidity index, derived from inpatient and
outpatient Medicare claims for the period extending from 13 months before
stage IV colorectal cancer diagnosis to 1 month before diagnosis.
†Based on Medicare claims filing.
‡Patient’s zip code of residence served as a proxy of socioeconomic status.
§Infusional includes IV FU or capecitabine.
Cetuximab or panitumumab.
Meyerhardt et al
610 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
RESULTS
Patient Demographics
We identified 2,526 patients diagnosed with stage IV colorectal
cancer between 2002 and 2007 and treated with fluoropyrimidine
therapy and either oxaliplatin or irinotecan within the first 6 months
of diagnosis (Table 1). Of these, 903 patients (36%) received bevaci-
zumab within 4 weeks of initiation of chemotherapy. Patients receiv-
ing bevacizumab were more likely to receive oxaliplatin (82.3%)
compared with patients not receiving bevacizumab (57.7%). Other-
wise, the distribution of tumor characteristics and patient demo-
graphics was similar between patients receiving and patients not
receiving first-line bevacizumab (Table 1).
Overall Survival With or Without Bevacizumab
The addition of bevacizumab to fluoropyrimidine and either
oxaliplatin or irinotecan led to a statistically significant improvement
in overall survival (Table 2) with an unadjusted hazard ratio (HR) of
0.87 (95% CI, 0.80 to 0.95; P  .003). Median overall survival was 19.0
months with bevacizumab and 15.9 months without bevacizumab
(Fig 2A). The adjusted HR was 0.85 (95% CI, 0.78 to 0.93). Similar
associations were observed adding propensity scores into the model.
In the subset of patients diagnosed between 2004 and 2007, the ad-
justed HR was 0.93 (95% CI, 0.84 to 1.02).
For patients who received oxaliplatin and fluoropyrimidine (Fig
2B), there was no apparent benefit of bevacizumab on survival (ad-
justed HR, 0.96; 95% CI, 0.86 to 1.07). In contrast, bevacizumab usage
was associated with an improved overall survival for patients treated
with irinotecan and fluoropyrimidine (P  .03; Fig 2C). The adjusted
HRs comparing bevacizumab to no bevacizumab with irinotecan
were 0.80 (95% CI, 0.66 to 0.97) in patients diagnosed between 2002
and 2007 and 0.86 (95% CI, 0.68 to 1.08) in patients diagnosed be-
tween 2004 and 2007. Bevacizumab-treated patients receiving irinote-
can, compared with patients not treated with bevacizumab, had
slightly greater use of second-line oxaliplatin (48.4% v 41.5%, respec-
tively) and epidermal growth factor receptor inhibitors (34.0% v
30.9%, respectively).
We explored the association between bevacizumab and overall
survival according to whether irinotecan was administered as a bolus
(IFL) or infusion (FOLFIRI; Fig 2D). Median overall survival was 18.1
months for IFL plus bevacizumab (n  31) compared with 13.0
months with IFL alone (n  548), with an adjusted HR of 0.72 (95%
CI, 0.48 to 1.09). Median overall survival was 18.1 months for
FOLFIRI with bevacizumab (n  128) compared with 13.3 months
with FOLFIRI only (n  139), with an adjusted HR of 0.88 (95 CI, 0.67
to 1.15).
Sensitivity Analyses
We defined first-line use of bevacizumab as receipt within 1
month of the first dose of cytotoxic chemotherapy. We tested an
alternative definition of bevacizumab within 6 months of start of
therapy; 396 additional patients received bevacizumab between 1 and
6 months of first dose of chemotherapy. With this definition, the
adjusted HR for bevacizumab effectiveness was 0.87 (95% CI, 0.80 to
0.95). In extending bevacizumab usage to within 6 months, the im-
proved survival observed with bevacizumab remained limited to
irinotecan-based chemotherapy (data not shown).
Bevacizumab-Associated Toxicities
We examined toxicities encountered within the first 2 and 6
months of initiation of chemotherapy (Table 3). Bevacizumab was
associated with a higher rate of stroke (4.9% v 2.5% without bevaci-
zumab) within the first 6 months of therapy. In contrast and contrary
to our expectation, the overall rate of cardiac events was less with
bevacizumab than without bevacizumab (11.5 v 14.5%, respectively).
We considered whether this discrepancy was related to bias by indica-
tion, whereby patients not receiving bevacizumab were more likely to
Table 2. HRs for Overall Survival Comparing First-Line Combination Chemotherapy With Bevacizumab to First-Line Combination Chemotherapy Without



























Yes 903 159 128 31 744 903 159 128 31 744
No 1,623 687 139 548 936 1,016 193 123 70 823
Overall survival
Unadjusted HR 0.87 0.81 0.83 0.82 0.97 0.93 0.85 0.79 0.91 0.96
95% CI 0.80 to 0.95 0.67 to 0.98 0.64 to 1.08 0.55 to 1.21 0.87 to 1.08 0.85 to 1.03 0.68 to 1.06 0.60 to 1.02 0.57 to 1.44 0.86 to 1.07
Adjusted HR by
multivariate
modeling† 0.85 0.80 0.88 0.72 0.96 0.93 0.86 0.88 0.83 0.95
95% CI 0.78 to 0.93 0.66 to 0.97 0.67 to 1.15 0.48 to 1.09 0.86 to 1.07 0.84 to 1.02 0.68 to 1.08 0.67 to 1.16 0.50 to 1.40 0.85 to 1.06
Adjusted HR by
propensity
scores† 0.85 0.80 0.83 0.74 0.96 0.93 0.83 0.85 0.90 0.95
95% CI 0.78 to 0.94 0.66 to 0.96 0.64 to 1.09 0.49 to 1.13 0.86 to 1.07 0.84 to 1.03 0.65 to 1.05 0.65 to 1.13 0.51 to 1.57 0.85 to 1.06
Abbreviations: FU, fluorouracil; HR, hazard ratio.
Infusional FU or capecitabine.
†Adjusting covariates include age, sex, race, comorbidity, marital status, primary tumor site, tumor grade, history of primary tumor surgery, median household
income, and regimen.
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have recent cardiac history (defined as within 12 months of initial
treatment). Among 166 patients with a history of an arterial throm-
botic event, 39% received bevacizumab. In those patients, there was
no difference in the rate of cardiac events associated with bevacizumab
within 6 months of first treatment (5.4% v 5.5% without bevaci-
zumab). However, patients who had not had a prior arterial event had
a lower rate of cardiac events with bevacizumab versus with bevaci-
zumab (6.1% v 9.0%, respectively). Adverse events within the first 12
months of therapy were similar to those within the first 6 months (data
not shown).
Rates of venous thrombosis were not appreciably different with
or without bevacizumab (20.4% v 21.1%, respectively). The rates of GI
tract perforation were significantly greater with versus without bevaci-
zumab (2.3% v 1.0%, respectively).
We explored rates of toxicities based on whether the cytotoxic
chemotherapy backbone was oxaliplatin or irinotecan. Rates of car-
diac events, strokes, deep venous thrombosis, and GI perforations
were comparable by chemotherapy (data not shown).
Mortality within 60 days of start of chemotherapy is a reported
end point in clinical trials.16 In this cohort, 4.9% of patients receiving
bevacizumab in first-line therapy died of any cause compared with
7.9% of patients not receiving bevacizumab (P  .004) within the first
60 days of therapy. This finding was consistent by number of




IFL only: median survival, 13.0 months; 95% CI, 11.6 to 14.0 months
IFL-BEV: median survival, 18.1 months; 95% CI, 8.4 to 29.7 months
FOLFIRI only: median survival, 13.3 months; 95% CI, 10.9 to 22.3 months
FOLFIRI-BEV: median survival, 18.1 months; 95% CI, 15.3 to 22.3 months 
FOLFOX/FOLFIRI/IFL only: median survival, 15.9 months; 
95% CI, 14.8 to 18.2 months
FOLFOX/FOLFIRI/IFL-BEV: median survival, 19.0 months; 























































































FOLFOX only: median survival, 19.2 months; 
95% CI, 17.6 to 20.2 months 
FOLFOX-BEV: median survival, 19.2 months; 
95% CI, 17.9 to 21.0 months
Irinotecan only: median survival, 13.0 months; 
95% CI, 11.8 to 14.1 months 
Irinotecan-BEV: median survival, 18.1 months; 
95% CI, 15.3 to 21.9 months




















































































Fig 2. Kaplan-Meier curves comparing overall survival for combination chemotherapy with or without bevacizumab (BEV): (A) either oxaliplatin or irinotecan with
fluoropyrimidine (n  1,484); (B) oxaliplatin with fluoropyrimidine (n  781); (C) irinotecan with fluoropyrimidine (n  703); and (D) subsets of irinotecan by
fluoropyrimidine delivery. (*) n  11; masked to protect patient confidentiality. FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil,
leucovorin, and oxaliplatin; IFL, irinotecan, fluorouracil, and leucovorin.
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were 4%, 7%, and 6% in patients receiving bevacizumab with comor-
bidity scores of 0, 1, or 2, respectively, and 7%, 9%, and 10% in
patients not receiving bevacizumab with comorbidity scores of 0, 1, or
2, respectively (P for interaction  .75). Similarly, there was no
interaction between 60-day mortality and surgery for primary tumor
(data not shown).
DISCUSSION
Randomized clinical trials have demonstrated that bevacizumab im-
proves overall and/or progression-free survival when added to first-
line cytotoxic chemotherapy in metastatic colorectal cancer.8,9,17
Using the SEER-Medicare linked database, we evaluated the effective-
ness of bevacizumab with combination chemotherapy in the Medi-
care population. The addition of bevacizumab to fluoropyrimidine
and either oxaliplatin or irinotecan led to a statistically significant
improvement in overall survival, although the benefit seemed limited
to patients receiving irinotecan-based chemotherapy regimens and
not evident in patients treated with oxaliplatin-based chemotherapy.
The addition of bevacizumab to cytotoxic chemotherapy increased
the rates of strokes and GI perforations but not cardiac events.
Bevacizumab was initially tested in colorectal cancer in a small,
randomized phase II trial with FU and leucovorin.18 The results led to
a phase III trial of IFL with or without bevacizumab that demonstrated
a significant improvement in median overall survival from 15.6 to 20.3
months (HR, 0.66; P  .001).8 By the time of FDA approval of
bevacizumab, IFL was no longer the preferred first-line regimen for
colorectal cancer. There was an increasing shift from IFL to FOLFOX
based on results from North Central Cancer Treatment Group trial
9741, showing a survival advantage with FOLFOX compared with IFL
Table 3. Bevacizumab-Associated Toxicities Comparing Treatment With Bevacizumab in Years 2004 to 2007 (n  903) to Treatment Without Bevacizumab
in Years 2002 to 2007 (n  1,623)
Toxicity
With Bevacizumab Without Bevacizumab





No. of Patients % No. of Patients % OR 95% CI OR 95% CI
Within 60 days of first chemotherapy
treatment
Cardiac, all 55 6.1 128 7.9 1.8 3.8 to 0.2 .10 0.69 0.49 to 0.96 0.68 0.48 to 0.95
No history of cardiac event or
stroke within 12 months of
diagnosis 25 2.8 73 4.5 1.7 3.0 to 0.3 .03 0.58 0.37 to 0.93 0.57 0.36 to 0.92
History of cardiac event or
stroke within 12 months of
diagnosis 30 3.3 55 3.4 0.1 1.5 to 1.4 .93 0.85 0.52 to 1.37 0.84 0.52 to 1.36
Stroke, all 13 1.4 16 1.0 0.4 0.5 to 1.4 .30 1.44 0.68 to 3.03 1.44 0.69 to 3.04
No history of cardiac event or
stroke within 12 months of
diagnosis † † 0.2 0.5 to 0.9 .50 1.44 0.53 to 3.90 1.51 0.55 to 4.12
History of cardiac event or
stroke within 12 months of
diagnosis † † 0.2 0.4 to 0.9 .56 1.53 0.50 to 4.69 1.50 0.49 to 4.64
Deep venous thrombosis or
pulmonary embolism 98 10.9 194 12.0 1.1 3.7 to 1.5 .41 0.89 0.68 to 1.15 0.88 0.68 to 1.15
GI perforation (n  18) † † 0.6 0.2 to 1.4 .08 2.15 0.83 to 5.54 2.17 0.84 to 5.65
60-day all-cause mortality
(n  172) 44 4.9 128 7.9 3.0 1.1 to 4.9  .01 0.58 0.41 to 0.84 0.59 0.41 to 0.84
Within 6 months of first chemotherapy
treatment
Cardiac, all 104 11.5 236 14.5 3.0 5.7 to 0.3 .03 0.71 0.55 to 0.92 0.70 0.54 to 0.91
No history of cardiac event or
stroke within 12 months of
diagnosis 55 6.1 146 9.0 2.9 5.0 to 0.8 .01 0.64 0.46 to 0.89 0.64 0.46 to 0.89
History of cardiac event or
stroke within 12 months of
diagnosis 49 5.4 90 5.5 0.1 2.0 to 1.7 .90 0.87 0.59 to 1.28 0.85 0.58 to 1.26
Stroke, all 44 4.9 41 2.5 2.4 0.8 to 3.9  .01 2.01 1.29 to 3.11 2.00 1.29 to 3.10
No history of cardiac event or
stroke within 12 months of
diagnosis 24 2.7 25 1.5 1.1 0.1 to 2.3 .05 1.76 1.00 to 3.12 1.75 0.99 to 3.10
History of cardiac event or
stroke within 12 months of
diagnosis 20 2.2 16 1.0 1.2 0.2 to 2.3 .01 2.22 1.12 to 4.39 2.21 1.11 to 4.38
Deep venous thrombosis or
pulmonary embolism 184 20.4 342 21.1 0.7 4.0 to 2.6 .68 0.96 0.78 to 1.18 0.96 0.79 to 1.18
GI perforation (n  18) 21 2.3 16 1.0 1.3 0.3 to 2.4  .01 2.36 1.21 to 4.60 2.43 1.24 to 4.75
Abbreviation: OR, odds ratio.
Adjusting covariates include age, sex, comorbidity, primary tumor site history of primary tumor surgery, and median household income.
†n  11; masked to protect patient confidentiality.
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(HR, 0.74; P  .0014).6 IFL was also supplanted in practice by
FOLFIRI. Likely because of these shifts in cytotoxic therapy backbone,
the FDA approved bevacizumab in combination with intravenous
FU-based chemotherapy, not restricting usage with only IFL but en-
abling usage of bevacizumab with FU alone, IFL, FOLFIRI, or
FOLFOX. Perhaps because bevacizumab is a biologic agent, and not a
cytotoxic agent, both oncologists and the FDA were more willing to
combine it with an infusional FU and irinotecan regimen or
oxaliplatin-based therapy, initially in the absence of efficacy data. For
many oncologists, FOLFOX and bevacizumab became the regimen of
choice in the United States. Two nonrandomized, observational
studies of patients receiving bevacizumab with combination chemo-
therapy (including IFL, FOLFOX, FOLFIRI, or capecitabine and
oxaliplatin) confirmed progression-free survival of 9.6 to 10.8
months,19,20 with one cohort reporting comparable progression-free
survival (although reduced overall survival) in elderly patients.19
However, these cohorts did not collect data from patients not receiv-
ing bevacizumab to serve as a comparison. Furthermore, most subse-
quent phase III trials of first-line therapy incorporate bevacizumab in
both arms of the study.7,21,22
The goal of effectiveness research is to understand the outcomes
of treatments as they are adopted by real-world practitioners who face
everyday treatment decisions in the face of multiple studies and pa-
tients whose attributes do not exactly correspond to the clinical trial
eligibilitycriteria.However,data fromaphaseIII trialofoxaliplatin-based
therapy with or without bevacizumab9 and our effectiveness results sug-
gest that the magnitude of benefit combining bevacizumab with oxalipla-
tin is more modest than originally observed for IFL and bevacizumab.
This difference by chemotherapy backbone may suggest a differential
benefit when bevacizumab is added to irinotecan compared with oxalip-
latin, although such a biologic interaction has not been reported.
We anticipated that the rates of major toxicities such as stroke,
perforation, and cardiovascular events would have been substantially
greater in the Medicare population than those encountered in the
efficacy studies. Notably, toxicities detected in our effectiveness cohort
are only marginally higher for bevacizumab-treated patients and are
similar to the rates reported in clinical trials. Administrative claims
data are not optimized for identification of certain bevacizumab-
associated adverse effects such as hypertension, proteinuria, and de-
layed wound healing. However, major toxicities such as stroke,
perforation, and myocardial infarction are well captured in billing
claims. Bevacizumab did not result in a substantially higher rate of
myocardial infarction or venous thrombosis in this cohort, although
there was a modestly higher rate of strokes and GI perforations.
The advantage of using the SEER-Medicare linked database is
that the choice of chemotherapy regimens is not limited to the strin-
gent treatment program required in clinical trials and analysis by
chemotherapy type is possible. Such analyses also capture the out-
comes of real-world usage of these medications, outside of protocol-
prescribed dose modifications and treatment holds.
Several limitations of this analysis must be noted. The potential
for inaccurate coding exists for any claims-based analysis, clinical
information available from billing records is not as detailed as from
chart reviews or clinical trials, and the details of dose modification
could not be captured.11 Our results may not generalize to the non-
Medicare population or the approximately 16% of Medicare benefi-
ciaries who receive care in a health maintenance organization setting,
where patterns of care may be different.23 However, because two
thirds of patients with colorectal cancer are over age 65 years and
Medicare is the primary insurer for the vast majority, our study rep-
resents the care received by typical US patients with colorectal cancer.
Because identification of recurrent cancer is challenging using admin-
istrative data, we restricted our cohort to patients with stage IV colo-
rectal cancer. Most clinical trials do not identify substantial differences
in prognosis for patients with stage IV disease and patients with recur-
rent metastatic disease. However, some caution is nonetheless war-
ranted because our results may not generalize to patients with
recurrent metastatic disease. In the context of an observational cohort
study, we cannot be certain that the survival differences we observed
are a result of bevacizumab or alternatively a result of baseline differ-
ences in patient attributes. Our baseline data do not demonstrate
appreciable differences in baseline characteristics, and we used pro-
pensity score modeling to adjust for potential biases. Nonetheless,
60-day mortality is greater in patients not receiving bevacizumab. This
difference may be a result of chance or an actual early benefit of
therapy that includes bevacizumab. Alternatively, patients receiving
bevacizumab may be different from patients not receiving bevaci-
zumab, and this difference may be associated with early mortality risk.
In conclusion, the addition of bevacizumab to first-line therapy
for metastatic colorectal cancer significantly improved overall survival
in a cohort derived from the linked SEER-Medicare database. The data
from this analysis suggest the benefit is derived from irinotecan-based
regimens, with marginal benefit in oxaliplatin-treated patients. Fur-
thermore, the benefit of bevacizumab was more attenuated in the
latter years when there was an increasing shift away from bolus to
infusional fluoropyrimidine regimens, increased availability of latter-
line epidermal growth factor inhibitors, and more aggressive surgical
management of limited stage IV disease. An ideal trial to answer the
question of whether bevacizumab benefit is truly limited to
irinotecan-based regimens would be a 2  2 randomization between
FOLFOX and FOLFIRI plus or minus bevacizumab. However, be-
cause multiple prior FOLFOX versus FOLFIRI trials have been re-
ported and suggest noninferiority between the two regimens (albeit
none have included bevacizumab),24,25 enthusiasm for such a trial
would be low. In summary, the routine use of bevacizumab in com-
bination with cytotoxic chemotherapy for Medicare beneficiaries with
stage IV colorectal cancer is associated with a modest survival advan-
tage and a modest excess risk of harms from perforation and stroke.
On balance, elderly patients with colorectal cancer can be counseled
that including bevacizumab in first-line therapy regimens for meta-
static colorectal cancer seems to be no more than marginally effective.
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